Nuvation Bio Stock Skyrockets on Analyst Coverage and Phase 3 Study Enrollment

Nuvation Bio's stock soared 15.7% after enrolling the first patient in a late-stage study of Ibtrozi for early stage non-small cell lung cancer and Jefferies initiated coverage with a buy rating and a $10 price target, representing a 210% upside potential. The company received US regulatory approval for Ibtrozi in June 2025 for treating locally advanced or metastatic ROS1+ NSCLC.

Nuvation Bio Inc. (NYSE: NUVB) reported the enrollment of the first patient in the TRUST-IV (NCT07154706) Phase 3 study, evaluating the efficacy and safety of IBTROZI (taletrectinib), a next-generation ROS1 inhibitor, versus placebo for the adjuvant treatment of patients with resected ROS1-positive (ROS1+) early-stage non-small cell lung cancer (NSCLC). The trial follows the recent approval of IBTROZI for locally advanced or metastatic ROS1-positive NSCLC in June 2025 Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI?? (Taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer^[1].

The TRUST-IV study will enroll approximately 180 patients in the U.S., Canada, Europe, Japan, and China with ROS1+ stage IB, II, or IIIA NSCLC who have undergone surgery for their disease. Patients must not have received adjuvant anticancer therapy except for standard postoperative platinum-based doublet chemotherapy. Participants will be randomized 2:1 to receive either taletrectinib or placebo daily. The primary endpoint is disease-free survival as determined by investigator Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer^[2].

Following the positive news, Nuvation Bio's stock surged by 15.7%, and Jefferies initiated coverage with a buy rating and a $10 price target, representing a 210% upside potential Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer^[2]. The company's focus on developing targeted therapies for challenging cancer types has drawn significant investor interest.